

8 March 2017



Cann Group receives medicinal cannabis cultivation licence from Australian Office of Drug Control

Melbourne-based Cann Group Limited (Cann Group) has been issued with a second licence under the Australian federal government's new regulatory system for medicinal cannabis use in Australia.

In addition to the cannabis research licence announced 17 February 2017, the company has now received the first commercial cultivation licence from the Australian Government's Office of Drug Control (ODC).

The new licence, MC001/17, issued to fully-owned Cann Group subsidiary Cannoperations Pty Ltd, allows Cann Group to produce Australian grown material that can be prescribed for patient use.

Cann Group is currently an unlisted public agribusiness company, focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia.

Cann Group's vision is to be a leading developer and supplier of cannabis, cannabis resin and medicinal cannabis products into the Australian market, and to supply overseas markets as those opportunities become available.

< ENDS >

For further information: <https://www.canngrouponlimited.com/>

Media requests / to arrange an interview contact:

Matthew Wright

NWR Communications

+61 (0) 451 896 420

matt@nwrcommunications.com.au